Anticorps Monoclonal anti-FABP4

FABP4 Monoclonal Antibody for WB, IHC, Indirect ELISA

Hôte / Isotype

Mouse / IgG2b

Réactivité testée

Humain, porc, rat, souris

Applications

WB, IHC, Indirect ELISA

Conjugaison

Non conjugué

CloneNo.

3E7E1

N° de cat : 67167-1-PBS

Synonymes

A FABP, AFABP, ALBP, aP2, FABP4, Fatty acid binding protein 4



Informations sur le produit

67167-1-PBS cible FABP4 dans les applications de WB, IHC, Indirect ELISA et montre une réactivité avec des échantillons Humain, porc, rat, souris

Réactivité Humain, porc, rat, souris
Hôte / Isotype Mouse / IgG2b
Clonalité Monoclonal
Type Anticorps
Immunogène FABP4 Protéine recombinante Ag8565
Nom complet fatty acid binding protein 4, adipocyte
Masse moléculaire calculée 132 aa, 15 kDa
Poids moléculaire observé 14 kDa
Numéro d’acquisition GenBankBC003672
Symbole du gène FABP4
Identification du gène (NCBI) 2167
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par protéine A
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

Fatty acid binding protein (FABP) 4 is a member of the FABP family which abundantly expressed, fatty acid carrier proteins. FABPs are capable of binding a variety of hydrophobic molecules such as long-chain fatty acids and are important for their uptake and intracellular trafficking. It was first identified as an adipocyte-specific protein, important for the maintenance of lipid and glucose metabolism. It is also detected in macrophages, where it participates in regulating inflammation and cholesterol trafficking via NFκB and PPAR. In more recent studies, FABP4 has been found in a variety of endothelial cells, where it has been identified as a target of VEGF and a regulator of cell proliferation and possibly angiogenesis. Pathologically, FABP4 has been associated with the development of metabolic syndrome, diabetes and cancer and vulnerability of atherosclerotic plaques. FABP4 has been identified as a novel prognostic factor for both adverse cardiovascular events and breast cancer.

{{ptg:RelatedPrimaryAntibodies}}